Dr. Reddy’s

Q2FY27 RESULTS UPDATE

23 OCTOBER 2026

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company’s business activities, please see the company’s annual report filed in Form 20-F with the US SEC for the fiscal year ended March 31, 2026, quarter ended June 30, 2026, and our other filings with US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

Q2FY27 Financial Highlights

Consistent double-digit base business^ growth, with EBITDA Margin @20.6%

Reported Revenues

₹ 8,671 Cr

1.5% YoY **7% QoQ**

EBITDA | EBITDA %

₹ 1,783 Cr | 20.6%

24% YoY **77% QoQ**

PBT | PBT %

₹ 1,228 Cr | 14.2%

33% YoY **122% QoQ**

***PAT | PAT %**

₹ 925 Cr | 10.7%

36% YoY **109% QoQ**

**Attributable to Equity shareholders*

- **Double-digit underlying base business^ YoY growth**
  - Reported YoY growth declined 1.5% due to lower lenalidomide sales
- **Reported EBITDA @20.6%**
- **Annualised RoCE @9.5%**
- **Net Cash** surplus at **₹2,502 Cr**

Note: Q1FY27 impacted by provision of ₹240 Cr towards inventory and other costs related to semaglutide API issue

^Excluding lenalidomide in North America

Q2FY27 Business Highlights

Steady progress across strategic priorities

- Partnered with **Takeda** for India's 1st Central Drugs Standard Control Organisation (CDSCO) approved dengue vaccine, **QDENGA**; to launch in private markets in H1 2027
- Expanded collaboration with **Gilead Sciences** for **investigational once-yearly lenacapavir** for HIV prevention in 120 countries
- In association with **GARDP Foundation**, secured **Thai FDA approval** for **zoliflodacin** for uncomplicated urogenital gonorrhoea treatment within 6 months of USFDA approval
- Secured approval for **rituximab** biosimilar from the **USFDA**
- Launched **nivolumab biosimilar** in India
- Generic **semaglutide** approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India
- **CDMO** business under **Aurigene Pharmaceutical Services** surpassed **$100+ million** in 12 months ended Sep'26

Qdenga® Dengue Tetravalent Vaccine (Live, Attenuated)

GILEAD

GARDP Global Antibiotic Research & Development Partnership

Reignite with NIVORZ® nivolumab 40 mg, 100 mg & 240 mg LIFE SAYS ONCE MORE



AURIGENE PHARMACEUTICAL SERVICES

Q2FY27 Other Highlights

ESG

- **'Silver'** medal by **FinanceAsia** in 'Best Large Cap Company in India' category at **Asia's Best Companies 2026**
- **Improved CRISIL ESG Rating** to **73/100** for **FY26** from 66/100 in FY25 - **only pharma company in leadership** category




OTHER UPDATES

- **On track** to resolve issue associated with semaglutide API, where certain batches were found to be out of specification
- **'VAI' classification** for API manufacturing facility in **Mirfield**, United Kingdom, following GMP inspection by USFDA in Sep'25
- Received a Form 483 with **3 and 4 observations respectively**, following a **PAI & GMP inspection** at **FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh** in Jul '26 and a GMP inspection at formulations manufacturing facility, FTO-3, in Bachupally, Hyderabad in Aug'26; responded within stipulated timeline
- Received a Form 2953 with **2 observations**, following a records assessment under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act at API manufacturing facility in **Mexico** between Jul and Sep'26; responded within stipulated timeline
- Received a Form 483 with **2 & 3 observations respectively**, following a PAI at formulation manufacturing facilities, **FTO-11** in Pydibhimavaram, Andhra Pradesh & **FTO-9** in Visakhapatnam, Andhra Pradesh in Oct'26; to respond within stipulated timeline

Q2FY27 Revenue Split

Double-digit base business* growth across key businesses, except Europe and API


REVENUE BY SEGMENT



Global Generics
₹ 7,793 Cr
0.7%YoY 8%QoQ

PSAI
₹ 831 Cr
12%YoY 2%QoQ

GLOBAL GENERICS SPLIT



North America
₹ 2,489 Cr
23%YoY 13%QoQ

Europe
₹ 1,393 Cr
1%YoY 3%QoQ

India
₹ 1,851 Cr
17%YoY 8%QoQ

Emerging Markets
₹ 2,059 Cr
24%YoY 12%QoQ


Branded businesses (India, Emerging Markets & NRT) account for 53% of revenues

**Excluding lenalidomide in North America*

Key Financial Metrics


Sustaining growth & profitability, while investing for the future

REVENUES
(₹ Cr)




*Excl. lenalidomide shelf stock adjustment (SSA), Q4 revenues ₹7,969Cr

GROSS MARGINS
(% of Revenues)




*49.4% excl. sema API related impact
^48% excl. SSA

SG&A
(% of Revenues)




*Excl. VAT liability, 33.4% of revenues excl. SSA

R&D
(% of Revenues)




*Excl. CAR-T charge, 6.8% of revenues excl. SSA

EBITDA MARGINS
(% of Revenues)




*15.4% excl. sema API related impact
^19.5%, excl. SSA, CAR-T charge, VAT liability
#24.8%, excl. provision related to new Labour Codes in India

DILUTED EPS
(₹)




RoCE (Annualized)
(%)




*8% excl. sema API related impact
^17.5%, excl. SSA, Impairment of CAR-T & Eftilagimod Alfa, VAT liability

CAPEX
(₹ Cr)




CASH FLOW
(₹ Cr)



*Before acquisition related payouts


NET DEBT / EQUITY



^Net Surplus (Adjusted for non-current cash & borrowings) stood at ₹ 2,502 Cr as on 30 Sep '26

Q2FY27 North America Performance

Continued double digit growth in base business*; reported growth impacted by lower lenalidomide sales




Revenues

₹ 2,489 Cr

23%YoY **13%QoQ**

Declined YoY due to lower lenalidomide sales.

Historical Revenues (₹ Cr)



*Includes impact of lenalidomide SSA of ₹453Cr

MARKET PERFORMANCE

12.4% vs 2.1%

DRL Growth vs US Generics Market
(Excl. lenalidomide)

*As per IQVIA MAT Aug' 26

NEW LAUNCHES

6	12
Q2FY27	YTD

NEW ANDA | NDA FILINGS

5 | 0	10 | 1
Q2FY27	YTD

PRICE EROSION

STABLE

PENDING APPROVAL

77	3
ANDAs	NDAs

Includes 47 Para IVs & 27 FTFs

As of Sep'26

KEY UPDATES

- **Double digit base business* growth in Q2FY27**, aided by new product launches, volume expansion and favourable foreign exchange currency fluctuations
- **First-to-market launch** of hospital drug, **sugammadex** injection




- Secured approval for **rituximab** biosimilar from the USFDA

*Excluding lenalidomide

Q2FY27 Emerging Markets Performance

Growth driven by new product launches across geographies, aided by favourable forex movements




Revenues

₹ 2,059 Cr

24%YoY **12%QoQ**

YoY Growth Drivers : New product launches, acquisitions and favourable forex.

Historical Revenues (₹ Cr)



COUNTRIES PRESENT IN

50

NEW PRODUCT LAUNCHES

27	70
Q2FY27	YTD

NEW FILINGS

31	56
Q2FY27	YTD

RUSSIA MARKET PERFORMANCE*

19.3% vs 21.3%


DRL Growth vs Russian Market

*As per IQVIA MQT Aug' 26

KEY UPDATES

- Secured approval for generic **semaglutide** in 8 emerging markets across Latin America, Africa, and the Middle East till date

REVENUE SPLIT



Russia ₹ 1,008 Cr

15%YoY **12% QoQ**

CISR ₹ 264 Cr


13%YoY **21% QoQ**

RoW ₹ 787 Cr

44%YoY **11% QoQ**

Q2FY27 India Performance

Moved up to #8 in IPM for the quarter, delivering consistent double-digit growth ahead of IPM




Revenues

₹ 1,851 Cr

17%YoY **8%QoQ**

Growth Drivers : New launches, acquired portfolios, price increases & volume growth.

Historical Revenues (₹ Cr)



MARKET PERFORMANCE*

21.0% vs 14.7%

*DRL MQT Growth vs IPM (Sep'26)

IPM RANK

#8 FTM & MQT Sep'26

#9 MAT Sep'26

THERAPY LEADERHIP*

#1 STOMATOLOGICALS

#2 VACCINES

NEW BRAND LAUNCHES

4 Q2FY27

11 YTD

₹100 CR+* BRANDS

24

BRANDS IN IPM TOP 300*

16

*As per IQVIA MAT Sep' 26

KEY UPDATES


- Partnered with **Takeda** for India's 1st CDSCO approved dengue vaccine, **QDENGA**; launch planned in private markets in first half of 2027
- Launched **nivolumab** biosimilar in India, marking entry into India's biosimilar immuno-oncology market
- Secured **1st abatacept IV** biosimilar approval in India
- **4 brands** in **Top 50 new launches** in IPM
- Distribution & promotion agreement with Novartis India terminated, following change in its controlling shareholding

Qdenga® Dengue Tetravalent Vaccine (Live, Attenuated)

Reignite with NIVORZ® nivolumab 40 mg, 100 mg & 240 mg LIFE SAYS ONCE MORE

Q2FY27 Europe Performance

Generics launch momentum & forex gains, partly offset by pricing pressure & NRT operating model changes




Revenues

₹ 1,393 Cr

1%YoY 3%QoQ

Growth Drivers : New product launches in generics, favourable forex, offset by price erosion and change in operating model following NRT integration

Historical Revenues (₹ Cr)



EU* COUNTRIES PRESENT IN

21

*Excludes NRT countries outside Europe

NEW GX PRODUCT LAUNCHES

6	30
Q2FY27	YTD


NEW FILINGS

3	4
Q2FY27	YTD

KEY UPDATES

- As reported in Q1FY27, NRT growth impacted by post-integration operating model changes; change is profit neutral

REVENUE SPLIT



NRT ₹ 658 Cr

6%YoY 0.3% QoQ

Germany ₹ 394 Cr

1%YoY 3% QoQ

UK ₹ 195 Cr


24%YoY 16% QoQ

Others ₹ 147 Cr

20%YoY 2% QoQ

Q2FY27 PSAI Performance

Lower API volume offtake impacting growth; CDMO business scales to $100 mn in annualized revenues




Revenues

₹ 831 Cr

12%YoY **2%QoQ**

Growth impacted by lower API volumes, partly offset by momentum in CDMO business, new product launches in API and favourable forex

Historical Revenues (₹ Cr)



GROSS MARGIN

11.8% vs 18.0%

Q2FY27 vs Q2FY26

GLOBAL DMF FILINGS

28	66
Q2FY27	YTD

US DMF FILINGS

2	2
Q2FY27	YTD

KEY UPDATES

- Expanded collaboration with **Gilead Sciences** for **investigational once-yearly lenacapavir** for HIV prevention in 120 countries, including India
- In association with **GARDP Foundation**, secured **Thai FDA** approval for **zoliflodacin** for uncomplicated urogenital gonorrhoea treatment within 6 months of USFDA approval
- **CDMO** business under Aurigene Pharmaceutical Services Limited (APSL) generated revenues of **$100+ million** in 12 months ended Sep'26
- **APSL** delivers **double digit growth** in Q2FY27
- APSL secured **long-term manufacturing & supply agreement** for USA, Europe, Canada & emerging markets with a leading global pharma co

.

GILEAD GARDP Global Antibiotic Research & Development Partnership AURIGENE PHARMACEUTICAL SERVICES

In Summary

A diversified business model with broad based levers

Strengthen Core Businesses, build future growth drivers
(Peptides, Biosimilars, Consumer Health, Innovative Assets)

Advance key products
(Semaglutide including re-launch, Abatacept)

Drive efficiencies through better operational leverage

Augment organic growth with **M&A and In-Licensing**

Enhance capabilities – People, Digital, Processes

Focus on **quality, compliance** and **sustainability**

About Key Metrics and Non-GAAP Financial Measures

This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts, as the case may be, from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in the press release.


Good Health Can’t Wait.